Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XC001 in CAD Patients Undergoing CABG
NCT07118449Phase 2Not yet recruiting
- Sponsor
- XyloCor Therapeutics
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of encoberminogene rezmadenovec in coronary artery disease (CAD) (2 arms), sponsored by XyloCor Therapeutics. Primary endpoint: Change from Baseline in treated segment(s) comparing XC001 and placebo in CMR imaging parameters at 26 weeks. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07118449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07118449.